MetaCap

Immunovant (IMVT) vs Krystal Biotech (KRYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Krystal Biotech (KRYS) has outperformed Immunovant (IMVT) over the past year, gaining 45.7% versus a gain of 40.6%. Over five years, KRYS leads with a +675.9% price change compared with +308.9% for IMVT. Krystal Biotech is the larger company by market cap ($9.15 billion vs $6.57 billion), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMVT+40.64%KRYS+45.69%
+104%+48%-8%
Nov 21, 20251 yearNov 20, 2026
IMVT+286.50%KRYS+489.82%
+650%+279%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMVT versus KRYS key metrics
MetricIMVTKRYS
Share price$31.77$308.89
Market cap$6.57B$9.15B
1-day change-2.31%-2.19%
YTD return+24.98%+25.29%
1-year return+40.64%+45.69%
5-year return+308.88%+675.91%
P/E ratio (TTM)—41.97
Forward P/E—33.47
EPS (TTM)$-2.56$7.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$389.13M
Revenue growth (YoY)—+33.94%
Net income (latest FY)$-505.61M$204.83M
Operating margin—41.45%
Net margin—52.64%
52-week high$45.42$382.54
52-week low$21.93$212.02
Distance from 52-week high-30.05%-19.25%
Analyst consensusbuystrong_buy
Avg. price target upside+53.07%+25.68%
Average volume1.42M283.88K
Shares outstanding206.95M29.63M
Employees315295
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

About Krystal Biotech

KRYS stock →

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees

IMVT vs KRYS FAQ

Which is bigger, Immunovant or Krystal Biotech?

Krystal Biotech (KRYS) is larger, with a market capitalization of $9.15B compared with $6.57B for Immunovant (IMVT).

Which stock has performed better over the past year, IMVT or KRYS?

KRYS returned +45.69% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.

Are Immunovant and Krystal Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons